Archive Press

PRESS RELEASES

20 June 2025 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011

12 June 2025 | non-Ad Hoc

Relief Therapeutics Announces Results of Annual General Meeting

22 May 2025 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

15 May 2025 | non-Ad Hoc

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

10 April 2025 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

6 March 2025 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

11 February 2025 | non-Ad Hoc

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

22 January 2025 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

27 December 2024 | non-Ad Hoc

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

16 December 2024 | non-Ad Hoc

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

13 December 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

11 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

4 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

29 October 2024 | non-Ad Hoc

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

25 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

21 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

8 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

4 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

23 September 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement

18 September 2024 | non-Ad Hoc

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

2 September 2024 | non-Ad Hoc

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

30 August 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

5 August 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Secures up to $11 Million from Royalty Sales

27 June 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting

3 June 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Executive Changes

30 May 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders

8 May 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives

30 April 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics has published its Annual Report

26 April 2024 | non-Ad Hoc

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting

27 March 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

22 March 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

28 February 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Renews CHF 50 million Share Subscription Facility

5 December 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth

22 November 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces CEO Transition

10 October 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone

15 September 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update

1 September 2023 | non-Ad Hoc

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

30 August 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics

19 July 2023 | non-Ad Hoc

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health

23 June 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East

23 June 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement

20 June 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders

16 June 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement

26 May 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

15 May 2023 | non-Ad Hoc

Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

12 May 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission

3 May 2023 | non-Ad Hoc

Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

1 May 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule

28 April 2023 | non-Ad Hoc

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

17 April 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100

14 April 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update

5 April 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Executive Leadership Team Change

4 April 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders

3 April 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board

22 March 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

17 March 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

16 March 2023 | non-Ad Hoc

Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

15 March 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™

28 February 2023 | non-Ad Hoc

Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars

14 February 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa

8 February 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Provides an Update on its Financing Strategy

17 January 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphoma

27 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

27 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

20 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

14 December 2022 | non-Ad Hoc

Relief Therapeutics to Participate in January Investor Meetings

13 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Issuance of Shares from Authorized Capital

8 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Executive Leadership Team Changes

21 November 2022 | non-Ad Hoc

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

16 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

14 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

8 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement

7 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

26 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement

25 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

14 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

10 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Announces U.S. Launch of PKU GOLIKE

6 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

3 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

22 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago

15 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Half-Year 2022 Results and Provides Corporate Update

12 September 2022 | non-Ad Hoc

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

7 September 2022 | non-Ad Hoc

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

24 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission

22 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation

17 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

12 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

3 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)

28 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease

28 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

21 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

18 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)

18 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

13 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU

8 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form

4 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

4 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk

21 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001

17 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

13 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil

8 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001

1 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA

31 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients

26 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19

23 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Expands U.S. Commercial Team

11 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

9 May 2022 | non-Ad Hoc

Relief Therapeutics to Participate in Industry and Investor Conferences in May

6 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

6 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA

22 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago

15 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Half-Year 2022 Results and Provides Corporate Update

12 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

7 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

24 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission

22 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation

17 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

12 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

3 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)

28 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease

28 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

21 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

18 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)

18 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

13 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU

8 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form

4 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

4 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk

21 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001

17 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

13 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil

8 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001

1 June 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA

31 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients

26 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19

23 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Expands U.S. Commercial Team

11 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

9 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Participate in Industry and Investor Conferences in May

6 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

6 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA

27 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE®

26 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

22 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil in a Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also Treated with Remdesivir and Continued to Progress

12 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

05 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process

01 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized Aviptadil When Given by Mouth Inhalation in Critically Ill Patients with COVID-19

01 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces that its Subsidiary, AdVita Lifescience GmbH, was Issued a Swiss Patent Entitled “Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis”

31 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Full-Year 2021 Results and Provides Corporate Update

28 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports In Vivo Data Published in the Peer Reviewed, International Journal of Molecular Sciences, Indicating Prolonged Release of Amino Acids Using Its PhysiomimicTM Technology May Have Benefits for the Treatment of PKU

24 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Receives Trademark Registration for RLF-100® From the U.S. Patent and Trademark Office

21 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales

21 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

17 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS- CoV-2 Infected Patients

15 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU

16 February 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment

08 February 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Files Trademark Application for RLF-100TM With the U.S. Patent and Trademark Office

01 February 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces That Its Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

31 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA

27 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences

27 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge

24 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs

19 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced Expansion of Aviptadil U.S. Expanded Access and Right to Try Programs for Patients With COVID-19 Respiratory Failure who Have Exhausted All Approved Therapies

14 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit

12 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Comments on Lawsuit Filed Against It by NeuroRx

06 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has announced that it has Submitted an Application to the FDA seeking Emergency Use Authorization for Aviptadil to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

04 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use

03 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA

30 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced it has Filed a Breakthrough Therapy Designation Request for Aviptadil in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

28 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports the Successful Conclusion of the Patent Examination Procedure for the Patent Application Entitled, “Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis”

16 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

15 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced a New, Favorable Safety Report for Aviptadil in the NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

10 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil

30 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Executive Changes

29 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Identified a Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir

24 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil

24 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence

18 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Launches Level 1 ADR Program in the United States

12 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information

11 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100™ (Aviptadil)

09 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development

05 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner’s Emergency Use Authorization Request for ZYESAMI®/RLF-100™ (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by the U.S. Food & Drug Administration

03 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced a Favorable, New Safety Report for Aviptadil in the National Institutes of Health Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

03 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Takes First Step to Create an ADR Program in the United States by filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

27 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients

26 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation

20 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn® AOS for Hard-to-Heal Ulcers

15 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced that the Journal of Infectious Diseases and Treatment has Published Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure

13 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil)

07 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100™ (Aviptadil)

07 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

06 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders

30 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in the Peer Reviewed Journal of Wound Care, Indicating That Nexodyn® AOS Is a Highly Effective Treatment to Support Wound Healing of Hard-to-Heal Leg Ulcers

30 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced a Second Favorable Safety Report for ZYESAMI™ (RLF-100TM/aviptadil) in the NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

28 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)

24 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Half-Year 2021 Results and Provides Corporate Update

21 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in the Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic™ Technology

13 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)

09 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE® KRUNCH in Germany and Italy

08 September 2021

Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

07 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021

02 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis

31 August 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced a New Finding from the ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

19 August 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

09 August 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders

03 August 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis

28 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita

28 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia

26 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces CHF 15 Million Private Placement

23 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil

22 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting

20 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19

13 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial

29 June 2021

Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR

21 June 2021

Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority

16 June 2021

Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19

02 June 2021

Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration

28 May 2021

Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer

27 May 2021

Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG

25 May 2021

Relief’s Partner Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA

18 May 2021

Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders

17 May 2021

Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

04 May 2021

Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR

22 April 2021

Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome

19 April 2021

Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.

15 April 2021

Relief Reports 2020 Financial Results and Provides Business Update

07 April 2021

Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir

07 April 2021

Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant

30 March 2021

Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100™ (aviptadil)

22 March 2021

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

15 March 2021

Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals

12 March 2021

Relief Announces CHF 10 Million Private Placement

08 March 2021

Relief Increases Issued Share Capital with Creation of Treasury Shares

24 February 2021

Relief Reports that NeuroRx Announced that RLF-100™ (Aviptadil) has Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28 Day Interim Endpoint

10 February 2021

Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100™ (aviptadil)

09 February 2021

Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors

08 February 2021

Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100™ (Aviptadil; ZYESAMI™) in Severe COVID-19 Patients

25 January 2021

Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

21 January 2021

Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM

20 January 2021

Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil

11 January 2021

Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial

05 January 2021

Relief Therapeutics to Participate in Virtual Investor Conferences in January

30 December 2020

Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

21 December 2020

Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer

18 December 2020

Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority

07 December 2020

Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

25 November 2020

Correction: NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients

24 November 2020

NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients

23 November 2020

Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG

18 November 2020

Relief Selects CRO and CDMO for RLF-100TM in Europe

13 November 2020

Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

05 November 2020

Relief Therapeutics and NeuroRx announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020

04 November 2020

Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team

13 October 2020

NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19

08 October 2020

Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer

30 September 2020

NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil)

28 September 2020

Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM

23 September 2020

Relief partner NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

21 September 2020

Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners

15 September 2020

Relief Reports Half-Year 2020 Results

04 September 2020

Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer

31 August 2020

Relief Announces Successful Up-listing from OTC Pink to OTCQB and Capital Increase from its Share Subscription Facility with GEM

20 August 2020

Relief Therapeutics and NeuroRx note submission of clinical results from 21 patient study for publication

06 August 2020

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure

03 August 2020

RLF-100 (aviptadil) clinical trial showe respiratory failure and inhibition of co human lung cells

29 July 2020

FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19

20 July 2020

RELIEF THERAPEUTICS Holding SA (SIX:RLF) shareholders approve all resolutions at its Ordinary General Meeting 2020 – Prof. Jonathan Javitt elected Vice Chairman of the Board of Directors

16 July 2020

RELIEF THERAPEUTICS Holding SA to agree share settlement for an outstanding CHF 1’723’300 debt position provided by GEM

16 July 2020

RELIEF THERAPEUTICS Holding SA to agree share settlement for an outstanding CHF 1’723’300 debt position provided by GEM

16 July 2020

NeuroRx and Relief Therapeutics announce Data Monitoring Committee determination to continue phase 2/3 trial of RLF-100 for Critical COVID-19

24 June 2020

NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19

17 June 2020

RELIEF THERAPEUTICS Holding SA (SIX:RLF) announces the report of its Ordinary General Meeting 2020

16 June 2020

NeuroRx and Relief Therapeutics announce Data Monitoring Committee determination to continue phase 2/3 trial of RLF-100 for Critical COVID-19

11 June 2020

Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital

08 June 2020

Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to all patients with Critical COVID-19 and Respiratory Failure

02 June 2020

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

25 May 2020

Relief Therapeutics (RLF:SIX) drug Aviptadil enters FDA trial at University of Miami, to treat COVID-19-induced Respiratory Distress Aviptadil targets the cytokine storm that causes fatal Respiratory Distress in COVID-19

14 May 2020

Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome

11 May 2020

Relief Therapeutics announces filing of IND for Phase 2/3 Clinical Trial of inhaled RLF-100 targeting early COVID-19 Lung Injury

06 May 2020

Relief Therapeutics Holding (RLF:SIX) drug Aviptadil enters FDA trial at NYU Langone Health, New York, to treat COVID-19-induced Acute Respiratory Distress

30 April 2020

RELIEF THERAPEUTICS Holding SA announces today the publication of its annual report for the year ended 2019 and provides corporate updates

09 April 2020

Relief Therapeutics (RLF:SIX) drug Aviptadil enters FDA trial at Thomas Jefferson University Hospital in Philadelphia, to treat COVID-19-induced Acute Respiratory Distress

02 April 2020

RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA

29 March 2020

FDA grants IND “Study May Proceed” for COVID-19 trial to NeuroRx, Inc. in partnership with RELIEF THERAPEUTICS (SIX:RLF) for treatment of Acute Respiratory Distress

25 March 2020

RELIEF THERAPEUTICS HOLDING SA (SIX:RLF) and NeuroRx, Inc. file FDA IND for Aviptadil to treat COVID-19-induced Respiratory Distress

17 March 2020

RELIEF THERAPEUTICS HOLDING SA (SIX: RLF) announces plans to test Aviptadil for the treatment of COVID-induced Acute Respiratory Distress Syndrome (ARDS). Compassionate care protocol to be conducted at Rambam Healthcare Campus in coordination with the Gov

11 March 2020

RELIEF THERAPEUTICS Holding SA (SIX: RLF) announces the proposal of Prof. Jonathan Javitt, M.D., M.P.H., at the upcoming general assembly as Vice Chairman of the Board

12 August 2019

RELIEF THERAPEUTICS Holding SA Announces Divestment of its Subsidiary Relief Therapeutics SA to Sonnet BioTherapeutics, Inc. to Ensure the Development of Atexakin Alpha (Interleukin-6)

02 August 2019

RELIEF THERAPEUTICS Holding SA announces termination of the agreements with Genclis and H&H Group

14 June 2019

RELIEF THERAPEUTICS Holding AG (SIX:RLF) announces today the results of its Annual General Meeting 2019

06 June 2019

RELIEF THERAPEUTICS Holding AG announces an increase of its capital consecutive to a draw down on its Share Subscription Facility

25 May 2019

RELIEF THERAPEUTICS Holding AG (SIX: RLF) announces significant change in its shareholding structure

24 May 2019

RELIEF THERAPEUTICS Holding AG (SIX: RLF) publishes the agenda for its 2019 Annual General Meeting

30 April 2019

RELIEF THERAPEUTICS Holding SA announces today the publication of its annual report for the year ended 2018

26 April 2019

RELIEF THERAPEUTICS Holding AG announces changes to its management structure

23 April 2019

RELIEF THERAPEUTICS Holding SA announces a Letter of Intent with ENTEROSYS SAS for the co-development of atexakin alfa towards novel indications

17 October 2018

RELIEF THERAPEUTICS Holding SA announces signature of service agreement with Genclis SA

18 September 2018

RELIEF THERAPEUTICS Holding SA announces the prolongation and raise of the amount from the Share Subscription Facility agreement with GEM

13 September 2018

RELIEF THERAPEUTICS Holding SA announces an out-licensing agreement with H&H Group

02 August 2018

RELIEF THERAPEUTICS Holding SA announces a formal commitment by GEM Global Yield Fund LLC SCS to amend and prolong the Share Subscription Facility (SSF) currently in effect

08 June 2018

RELIEF THERAPEUTICS Holding AG (SIX: RLF) publishes the agenda for its 2018 Annual General Meeting

02 June 2018

RELIEF THERAPEUTICS Holding AG (SIX:RLF) announces today the results of its Annual General Meeting 2018

23 April 2018

RELIEF THERAPEUTICS Holding SA announces that it has granted an option to license Aviptadil to Seren Clinical

09 April 2018

RELIEF THERAPEUTICS Holding SA announces an in-licensing agreement with Genclis SA

06 November 2017

RELIEF THERAPEUTICS Holding SA announces an agreement with the University of Freiburg for the clinical development of Aviptadil in Sarcoidosis

07 October 2017

RELIEF THERAPEUTICS Holding SA announces the exercise of warrants by GEM

07 July 2017

Relief Therapeutics Holding SA announces the resignation of David A. Lowe from his position of member of the Board of Directors

31 May 2017

RELIEF THERAPEUTICS Holding AG (SIX:RLF) announces today the results of its Annual General Meeting 2017 and its Board appointments for 2017

09 May 2017

RELIEF THERAPEUTICS Holding AG (SIX: RLF) publishes the agenda for its 2017 Annual General Meeting

25 October 2016

Relief Therapeutics Holding AG and FirstString Research Inc. announce a strategic collaboration for the development of atexakin alfa

06 October 2016

PX’Therapeutics and RELIEF THERAPEUTICS Holding AG announce a strategic collaboration agreement

28 July 2016

RELIEF THERAPEUTICS Holding AG announces signing of a term sheet to acquire FirstString Research, Inc.

18 July 2016

RELIEF THERAPEUTICS Holding AG announces today the completion of the business combination with Relief Therapeutics SA and the conversion of a CHF 3.3M convertible loan

28 June 2016

THERAMetrics holding AG (SIX:TMX) announces today that it expects to conclude its business combination with Relief Therapeutics SA by mid-July 2016

06 June 2016

THERAMetrics holding AG announces today an agreement to sell its Italian CSS subsidiary

26 May 2016

THERAMetrics holding AG (SIX:TMX) announces today the results of its Annual General Meeting 2016 and its Board appointments for 2016.

02 February 2022